-+ 0.00%
-+ 0.00%
-+ 0.00%
Shionogi completes USD 2 billion acquisition of IntraBio
Share
Listen to the news
Shionogi completes USD 2 billion acquisition of IntraBio
  • Shionogi completed its USD 2 billion acquisition of all outstanding IntraBio shares, expanding its rare disease portfolio.
  • The deal, agreed on October 5, 2026, includes global intellectual property and commercialization rights for AQNEURSA (levacetylleucine).
  • AQNEURSA has U.S. and European approval for neurological manifestations of Niemann-Pick disease type C, plus U.S. approval for ataxia in Ataxia-Telangiectasia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shionogi & Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611171900BIZWIRE_USPR_____20261117_BW876530) on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending